A Phase 2 Study of Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma
Latest Information Update: 24 May 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; Daratumumab (Primary) ; Nivolumab (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms NIVO/DARA study
- 21 May 2024 Status changed from active, no longer recruiting to completed.
- 12 May 2023 Planned End Date changed from 1 Apr 2024 to 25 Jan 2024.
- 12 Oct 2022 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.